# HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma

**Authors:** Yeonhwa Song, Seungeun Lee, So-Won Heo, Juliane Spohn, Dominik Schmiedel, Taemoo Heo, Sanghwa Kim, Jongmin Park, Haeng Ran Seo

PMC · DOI: 10.3390/ijms262110329 · 2025-10-23

## TL;DR

HO-1197, a new herbal medicine, shows strong anticancer effects in liver cancer by targeting multiple pathways and improving immune response.

## Contribution

HO-1197 is a novel herbal formulation with multifaceted anticancer mechanisms, including cell cycle arrest, anti-angiogenesis, anti-metastasis, and immune modulation.

## Key findings

- HO-1197 selectively inhibits HCC cell viability without hepatotoxicity and is more effective than sorafenib.
- HO-1197 induces apoptosis and G2/M arrest via ROS-mediated DNA damage, independent of p53 status.
- HO-1197 modulates the tumor immune microenvironment and synergizes with sorafenib in preclinical models.

## Abstract

Hepatocellular carcinoma (HCC) is the most prevalent primary malignancy of the liver. Characterized by rapid progression and poor overall survival rates, HCC requires effective and streamlined treatment regimens. It predominantly occurs in East Asia and sub-Saharan Africa, where it has historically been managed with herbal formulas. We previously observed that the herbal formula HO-1089 exerts potent anti-HCC effects both in vitro and in vivo. In this study, we investigated the anticancer efficacy and mechanisms of HO-1197, a reconstituted herbal formulation derived from HO-1089. HO-1197 selectively inhibited the viability of HCC cell lines without hepatotoxicity and demonstrated superior anticancer activity compared with both HO-1089 and sorafenib. Mechanistically, HO-1197 induced apoptosis and G2/M arrest through reactive oxygen species-mediated DNA damage, independent of p53 status. Transcriptomic analysis revealed downregulation of mitosis-related genes, particularly those regulated by FOXM1, a key driver of HCC proliferation and metastasis. HO-1197 suppressed FOXM1 expression and nuclear translocation, reducing its downstream targets and diminishing angiogenic and metastatic potential. Furthermore, HO-1197 modulated the tumor immune microenvironment by promoting pro-inflammatory macrophage polarization and enhancing natural killer cell-mediated cytotoxicity. HO-1197 exhibited potent antitumor efficacy, and combination therapy with HO-1197 and sorafenib exhibited synergistic effects in both two-dimensional and immune-activated multicellular spheroid models. These findings suggest that HO-1197 is a promising multifunctional therapeutic candidate with antitumor, antiangiogenic, antimetastatic, and immunomodulatory properties. Its combination with sorafenib may offer effective treatment for HCC. HO-1197, which demonstrated strong efficacy, is a novel herbal medicine developed by H&O Biosis and is referred to as an Integrated Natural Medicine.

## Linked entities

- **Genes:** FOXM1 (forkhead box M1) [NCBI Gene 2305], TP53 (tumor protein p53) [NCBI Gene 7157]
- **Diseases:** Hepatocellular carcinoma (MONDO:0007256), HCC (MONDO:0007256)

## Full-text entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, FOXM1 (forkhead box M1) [NCBI Gene 2305] {aka FKHL16, FOXM1A, FOXM1B, FOXM1C, HFH-11, HFH11}
- **Diseases:** HCC (MESH:D006528), Tumor (MESH:D009369), inflammatory (MESH:D007249), Metastasis (MESH:D009362), primary malignancy (MESH:D001932)
- **Chemicals:** reactive oxygen species (MESH:D017382), HO-1089 (-), sorafenib (MESH:D000077157)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12609843/full.md

---
Source: https://tomesphere.com/paper/PMC12609843